Pacira Pharmaceuticals (PCRX) Receiving Somewhat Favorable Press Coverage, Accern Reports
News headlines about Pacira Pharmaceuticals (NASDAQ:PCRX) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pacira Pharmaceuticals earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.3518321733582 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s scoring:
- Bank of America Corporation Lowers Pacira Pharmaceuticals, Inc. (PCRX) Price Target to $45.00 (americanbankingnews.com)
- Pacira Pharmaceuticals, Inc. :PCRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 (finance.yahoo.com)
- ETFs with exposure to Pacira Pharmaceuticals, Inc. : October 2, 2017 (finance.yahoo.com)
- Pacira Pharmaceuticals CEO to Testify at White House Opioid Crisis Commission Meeting – GlobeNewswire (press release) (globenewswire.com)
- Pacira Pharmaceuticals Inc (PCRX) Receives New Coverage from Analysts at Goldman Sachs Group, Inc. (The) (americanbankingnews.com)
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 1.79% during midday trading on Thursday, hitting $36.95. 962,297 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $37.01 and its 200-day moving average is $43.46. The stock’s market cap is $1.49 billion. Pacira Pharmaceuticals has a 1-year low of $29.95 and a 1-year high of $58.95.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The firm had revenue of $70.90 million for the quarter, compared to analyst estimates of $73.37 million. During the same period in the previous year, the firm posted $0.21 earnings per share. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. Analysts predict that Pacira Pharmaceuticals will post ($0.17) earnings per share for the current fiscal year.
A number of research firms have recently commented on PCRX. BMO Capital Markets cut their target price on shares of Pacira Pharmaceuticals from $42.00 to $40.00 and set a “market perform” rating for the company in a research note on Thursday, August 3rd. Bank of America Corporation cut their target price on shares of Pacira Pharmaceuticals from $46.00 to $45.00 and set a “buy” rating for the company in a research note on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $87.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, June 21st. Canaccord Genuity reaffirmed a “buy” rating and set a $56.00 price objective on shares of Pacira Pharmaceuticals in a research note on Monday, July 31st. Finally, HC Wainwright set a $59.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company’s stock. Pacira Pharmaceuticals currently has an average rating of “Hold” and an average price target of $52.07.
COPYRIGHT VIOLATION NOTICE: “Pacira Pharmaceuticals (PCRX) Receiving Somewhat Favorable Press Coverage, Accern Reports” was first published by Marea Informative and is the property of of Marea Informative. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at http://www.mareainformativa.com/pacira-pharmaceuticals-pcrx-receiving-somewhat-favorable-press-coverage-accern-reports/117859/.
In related news, Director Paul J. Hastings sold 1,044 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total value of $37,740.60. Following the sale, the director now directly owns 3,518 shares of the company’s stock, valued at $127,175.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Kristen Marie Williams sold 3,461 shares of the company’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total transaction of $127,191.75. Following the completion of the sale, the chief accounting officer now directly owns 21,312 shares in the company, valued at $783,216. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,390 shares of company stock worth $1,215,480. Corporate insiders own 6.60% of the company’s stock.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.